Oncology
2 drugs are in development for Uveal Melanoma.
- Companies
- 2
- Clinical trials
- 14
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Uveal Melanoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(2)
| Drug | Company |
|---|---|
| Bel-sar | Aura Biosciences, Inc. (AURA) |
| Darovasertib | IDEAYA Biosciences, Inc. (IDYA) |
About this indication
Uveal Melanoma context
Oncology·MeSH: Uveal Melanoma (D000098943)
Also known as: Melanoma Of The Uvea, Melanoma, Intraocular, Melanoma, Ocular
Narrower concepts tracked separately: Choroidal Melanoma
Prevalence
75.0 / 100K
Incidence
23.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Uveal Melanoma?
BioSniper tracks 2 drugs in development for Uveal Melanoma across 2 companies.
How many clinical trials target Uveal Melanoma?
There are 14 clinical trials targeting Uveal Melanoma tracked by BioSniper.
What is the prevalence of Uveal Melanoma?
The estimated prevalence of Uveal Melanoma is approximately 75.0 per 100,000 population.